APRE · Aprea Therapeutics Inc
United States · RS rating 10 · As of 2026-10-14
| Price | 0.58 USD |
|---|---|
| 1-day change | -2.8% |
| RS rating (overall / 1M / 3M / 12M) | 10 / 10 / 24 / 11 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 25 / 9 / 46 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +31.9% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +64.7% |
| Market cap (USD) | $10.6M |